HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study

Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a. We assessed HBsAg loss with 48- and 96-week Peg-IFN alfa-2a in chronic hepatitis B pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical and translational hepatology 2018-03, Vol.6 (1), p.25-34
Hauptverfasser: Hu, Peng, Shang, Jia, Zhang, Wenhong, Gong, Guozhong, Li, Yongguo, Chen, Xinyue, Jiang, Jianning, Xie, Qing, Dou, Xiaoguang, Sun, Yongtao, Li, Yufang, Liu, Yingxia, Liu, Guozhen, Mao, Dewen, Chi, Xiaoling, Tang, Hong, Li, Xiaoou, Xie, Yao, Chen, Xiaoping, Jiang, Jiaji, Zhao, Ping, Hou, Jinlin, Gao, Zhiliang, Fan, Huimin, Ding, Jiguang, Zhang, Dazhi, Ren, Hong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a. We assessed HBsAg loss with 48- and 96-week Peg-IFN alfa-2a in chronic hepatitis B patients with partial response to a previous NA. Hepatitis B e antigen (HBeAg)-positive patients who achieved HBeAg loss and hepatitis B virus DNA
ISSN:2225-0719
2310-8819
DOI:10.14218/JCTH.2017.00072